{"id":2572,"date":"2017-09-26T16:52:59","date_gmt":"2017-09-26T16:52:59","guid":{"rendered":"https:\/\/www.medicalmarijuanainc.com\/?p=29275"},"modified":"2017-09-26T16:52:59","modified_gmt":"2017-09-26T16:52:59","slug":"medical-marijuana-inc-subsidiary-hempmeds-brasil-sponsor-8th-abn-rjanerj-congress-rio-de-janeiro","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/09\/26\/medical-marijuana-inc-subsidiary-hempmeds-brasil-sponsor-8th-abn-rjanerj-congress-rio-de-janeiro\/","title":{"rendered":"Medical Marijuana, Inc. Subsidiary HempMeds\u00ae Brasil To Sponsor 8th ABN-RJ\/ANERJ Congress in Rio de Janeiro"},"content":{"rendered":"

SAN DIEGO, Sept. 26, 2017 — <\/span>Medical Marijuana, Inc.<\/span><\/a> (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary <\/span>HempMeds\u00ae Brasil <\/span><\/a>is proud to sponsor the <\/span>8th Brazilian Academy of Neurology\/Association of Neurology of the State of Rio de Janeiro (ABN-RJ\/ANERJ) Congress Workshops<\/span><\/a> taking place from September 28-30 at the Windsor Barra Convention Center in Rio De Janeiro, Brazil.<\/span><\/p>\n

The 8th ABN-RJ\/ANERJ Congress aims to bring together professionals working in Neurology\/Neurosciences and related fields to deepen the scientific debate and the development of knowledge in leading areas such as neurogenetics, neuroimaging, neuroimmunology, translational neurology, among others.<\/span><\/p>\n

“We are proud to sponsor this neurological-focused event that we believe will focus attention toward improving the quality of treatment for people with neurological disorders,” said Medical Marijuana, Inc.’s CEO Dr. Stuart Titus. “With its neuroprotective, anti-oxidative and anti-inflammatory effects, cannabidiol (CBD) is making new inroads into neurological research. Given potential neuro-regenerative effects, CBD further holds the potential to revolutionize neurological medicine. \u00a0By showing great promise for neurodegenerative diseases like Parkinson’s, Alzheimer’s, Multiple Sclerosis and Epilepsy – we continue to be excited about research opportunities throughout Latin America. We are further encouraged by the Brazilian medical community’s interest in new treatment solutions that cannabis and CBD may offer to improve the quality of patient’s lives.”<\/span><\/p>\n

HempMeds Brasil\u2122<\/span><\/a> is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. Most recently in February 2017, for the filling of a prescription for the first time for the Company’s hemp CBD oil product RSHO\u2122 to treat patients in the Country suffering from Multiple Sclerosis. Additionally, doctors in Brazil can prescribe RSHO\u2122 for any condition and <\/span>HempMeds Brasil\u2122<\/span><\/a> has worked with several cases including patients suffering from:<\/span><\/p>\n